Hanyoyi na gefe, Gargadi, da Sauran Bayanan Mahimmanci
Simponi (golimumab) wani nau'i ne na miyagun ƙwayoyi wanda aka sani da TNF-alpha ( kututture necrosis factor alpha ). An gano cewa TNF tana taka muhimmiyar rawa wajen ci gaba da cututtukan cututtuka na huhu (IBD). An gano TNF a mafi girma a cikin mazaunan maza da ciwon cututtuka da cututtukan Crohn fiye da yadda suke cikin mutanen da ba su da wani nau'i na IBD.
Simponi, kamar sauran magunguna masu amfani da kwayoyin cutar da ke amfani da su na IBD, suna ɗaure zuwa TNF-alpha kuma suna hana shi daga jiki. Wannan magani ne Janssen Biotech ke haɓaka.
Masu bincike sunyi tunanin cewa TNF-alpha yana da tasiri a cikin kamfanin IBD da tsarin tsarin gastrointestinal. IBD shine yanayin mummunan yanayi, kuma TNF-alpha ne manzo ne wanda aka sani da cytokine . Cytokines ba wai kawai suna adana "sakonni" tsakanin kwayoyin halitta ba, amma kuma suna taka muhimmiyar rawa wajen inganta kullun kumburi.
Ta yaya Simponi Taken?
Ana ba Simponi a matsayin allura karkashin fata. Bayan an horar da su daga likitocin kiwon lafiya, marasa lafiya zasu iya ba da kansu Simponi allura a gida. Za a zo da haruffan bayani game da amfani da su, kuma likitan mai ba da umurni zai ba da wasu umarni na musamman waɗanda marasa lafiya zasu bi. Da farko Simponi, akwai 2 injections don farawa. Na gaba, an bada 1 allura 2 makonni daga baya.
Bayan haka, don tabbatarwa, ana bada simintin Simponi kowane mako 4.
Yana amfani
An yarda da Simponi don magance cututtuka mai tsaka-tsaka mai tsaka-tsaka a cikin lokuta da basu amsa ga magunguna mafi mahimmanci ba (ba a yi amfani dasu a matsayin magunguna na farko ba don yanayin). An kuma yarda Simponi ya bi da cututtuka na rheumatoid , cututtuka na psoriatic, da kuma sparkylitis ankylosing.
Simponi yayi aiki don hana ƙonewa ta hanyar haɗawa zuwa TNF-alpha. Lokacin da TNF-alpha ba ya samuwa don haifar da kumburi, IBD na iya shigar da lokacin gyarewa (lokacin da cututtukan cututtuka da bayyanar cututtuka sun kasance).
Wanda ba za a dauka Simponi ba?
Ka gaya wa likitanka idan ana kula da ku saboda kamuwa da cuta, idan kun kasance mai ciwon cutar cutar hepatitis B, kwanan nan ya sami maganin alurar riga kafi, ko kuma ya taba samun rashin lafiyar zuwa Simponi.
Hanyoyin Gaba
Abubuwa masu rikitarwa na Simponi sun haɗa da kamuwa da cutar na numfashi na sama, maganin injection (irin su redness ko kumburi), da cututtukan cututtuka irin su mura da sanyi . Faɗa wa likitanka idan duk wani tasirin da ke cikin ƙasa ya damu ko kada ka tafi. Wajibi ne ya kamata a ba da labari ga likita a nan da nan.
Sauran Gargaɗi akan Hanyoyin Cutar
Simponi da sauran magungunan TNF-blocker sun haɗa da wasu kamuwa da cuta, ciki har da tarin fuka. Duk wani abin da ke nunawa ga mutumin da ke da tarin fuka ya kamata a bayar da rahoton ga likita mai ladabi. Dole ne gwada marasa lafiya tare da Simponi gwadawa akan tarin fuka (ciki har da irin wannan cuta), da kuma shan magani idan ya cancanta. Duk da yake shan wannan magani, wajibi ne a kula da marasa lafiya don alamun ko alamu na tarin fuka, irin su:
- Ƙunƙun zuma
- Ƙara
- Fever
- Rashin ci
- Sumi dare
- Asarar nauyi
Sauran nau'in cututtuka ma yana yiwuwa, kamar yadda wannan magani yana rage ƙarfin jiki na jurewa ga magunguna. Marasa lafiya waɗanda suka yi tafiya zuwa yanki da ke da mummunar tasiri na cututtukan fungal ko wadanda ke da kamuwa da cuta a yanzu suna bada rahoto ga waɗannan likitoci ga likitan likitan Simponi.
Ma'aikatan TNF sun hade da ci gaban wasu cututtuka. An ruwaito Lymphoma a cikin mutanen da ke dauke da 'yan bindigar TNF. Musamman, haɗarin ƙwayar lymphoma T-cell t-cell tayi girma, musamman ga samari.
Simponi ya hade da ci gaban ciwon daji . Mutane da suke amfani da Simponi sun kasance suna sane da kowane canje-canje a cikin fata, irin su sabon growths ko moles wanda canzawa a launi ko siffar.
Mutanen da ke ɗauke da cutar cutar hepatitis B suna da haɗari don sake dawo da kwayar cutar yayin shan magungunan TNF. Dole ne a gwada marasa lafiya da suka ɗauki Simponi don cutar hepatitis B kuma ya kamata su kasance masu lura da alamu da bayyanar cututtuka na hepatitis B kamar:
- Hannu
- Ƙungiyoyin launi masu launin launi
- Darkin fitsari
- Babban gajiya
- Fevers
- Rashin ci
- Muscle aches
- Skin rashes
- Ciki mara tausayi
- Vomiting
- Yellow fata ko idanu
An lura da ƙananan jini a wasu marasa lafiya dauke da kwayoyin TNF. Wannan damuwa ne na musamman ga mutanen da ke tare da IBD, waɗanda suke da hatsari ga ƙananan matakan jini. Likitanka zai lura da jininka a lokuta na lokaci don neman anemia .
Sauran matsalolin da zasu iya faruwa yayin da suke shan maganin TNF sun hada da ciwon zuciya, ƙwararrun sclerosis, ciwo na Guillain-Barré, ciwon hanta, psoriasis, da lupus-like symptoms.
Ciniki da Drug Interactions
Ana amfani da simponi tare da wasu kwayoyi da ake amfani dasu don biyan IBD kamar corticosteroids. Magunguna da zasu iya hulɗa tare da Simponi sun haɗa da:
- Kineret (anakinra)
- Orencia (abatacept)
- Rituxan (rituximab)
- Rayayyun alurar rigakafi
Babu dangantaka da aka sani da abinci.
Tsaro a lokacin ciki
FDA ta kirkiro Simponi a matsayin likitanci na B. Abinda Simponi ya yi game da yaron da ba a haifa ba an yi nazari sosai. Dole ne kawai a yi amfani da Simoponi a lokacin daukar ciki idan an buƙata da gaske. Sanar da likitan likita idan kun yi ciki yayin shan Simponi. Ba a sani ba idan Simponi ya shiga madara nono, duk da haka wasu abubuwa masu kama da juna sun nuna su shiga cikin madara nono. Ana iya auna yiwuwar yin tasiri mai tsanani a cikin jarirai a kan amfani da magani ga uwar. Wani zabin shine ya daina shan nono kafin gudanarwa Simponi.
Sources:
Janssen Biotech, Inc. "Shirye-shiryen Abincin Simponi." Mayu 2013.
Janssen Biotech, Inc. "Simponi Yanar Gizo." Mayu 2013.
Olsen T, Goll R, Cui G, et al. "Matakan jikin ƙwayoyin cutar necrosis factor-alpha ya danganta da saƙar kumburi a cikin cututtukan da ba a yi musu ba." Scand J Gastroenterol . 2007 Nuwamba; 42: 1312-1320.
Roberts-Thomson IC, Fon J, Uylaki W, Cummins AG, Barry S. "Sarkani, cytokines da cututtuka na ƙwayar cututtukan jini: hangen nesa." Gwani Rev Gastroenterol Hepatol . 2011 Dec; 5: 703-716. Doi: 10.1586 / egh.11.74.